Oncolytics Biotech Discloses American Society of Clinical Oncology Annual Meeting Abstracts, Highlights Pelareorep's Potential In Pancreatic Cancer And Immunotherapeutic Mechanism Of Action
Oncolytics Biotech Discloses American Society of Clinical Oncology Annual Meeting Abstracts, Highlights Pelareorep's Potential In Pancreatic Cancer And Immunotherapeutic Mechanism Of Action
One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The second describes pelareorep's ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response. The ASCO annual meeting will take place from May 31 – June 4, 2024, in Chicago, Illinois.
其中一份是正在進行的試驗摘要，討論了GOBLET研究的第5組，該研究將評估在新診斷的轉移性胰腺導管腺癌（PDAC）患者中使用pelareorep和改性FOLFIRINOX（mfolfirinox）與阿替珠單抗和不含阿替唑單抗的組合。第二部分描述了pelareorep在多種癌症中誘導腫瘤浸潤淋巴細胞（TIL）擴張的能力以及TIL擴張與腫瘤反應之間的相關性。ASCO 年會將於 2024 年 5 月 31 日至 6 月 4 日在伊利諾伊州芝加哥舉行。